149 related articles for article (PubMed ID: 31432632)
1. JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma.
Kim MS; Park CJ; Cho YU; Jang S; Seo EJ; Park CS; Huh J; Im HJ; Seo JJ; Yoon DH; Suh C
Ann Lab Med; 2020 Jan; 40(1):1-6. PubMed ID: 31432632
[TBL] [Abstract][Full Text] [Related]
2. Expression of JL1 in Burkitt lymphoma is associated with improved overall survival.
Hwang I; Go H; Jeon YK; Ko YH; Yoon DH; Suh C; Huh JR; Lee H; Gil M; Park CS
Virchows Arch; 2011 Oct; 459(4):353-9. PubMed ID: 21814778
[TBL] [Abstract][Full Text] [Related]
3. Expression of leukemia-associated antigen, JL1, in bone marrow and thymus.
Shin YK; Choi EY; Kim SH; Chung J; Chung DH; Park WS; Jung KC; Kim HS; Park S; Kim HJ; Park MH; Min CK; Kim CC; Park SH
Am J Pathol; 2001 Apr; 158(4):1473-80. PubMed ID: 11290565
[TBL] [Abstract][Full Text] [Related]
4. The Incidence and Immunophenotypic and Genetic Features of JL1 Expressing Cells and the Therapeutic Potential of an Anti-JL1 Antibody in
Park SH; You E; Park CJ; Jang S; Cho YU; Yoon CH; Koh KN; Im HJ; Seo JJ
Ann Lab Med; 2019 Jul; 39(4):358-366. PubMed ID: 30809981
[TBL] [Abstract][Full Text] [Related]
5. Expression of JL1 is an effective adjunctive marker of leukemia cutis.
Park YS; Park SH; Park SJ; Kim Y; Jang KT; Ko YH; Lee MW; Huh JR; Park CS
Arch Pathol Lab Med; 2010 Jan; 134(1):95-102. PubMed ID: 20073611
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens.
Wang W; Li Y; Ali H; Zhao L; Mei D; Hu W; Jiang B
BMC Cancer; 2021 Dec; 21(1):1315. PubMed ID: 34879826
[TBL] [Abstract][Full Text] [Related]
7. Lymphoblastic lymphoma.
Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
[TBL] [Abstract][Full Text] [Related]
8. A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias.
Park WS; Bae YM; Chung DH; Kim TJ; Choi EY; Chung JK; Lee MC; Park SY; Park MH; Park SH
Leukemia; 1998 Oct; 12(10):1583-90. PubMed ID: 9766503
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow biopsy in non-Hodgkin lymphoma: a morphological study.
Kumar S; Rau AR; Naik R; Kini H; Mathai AM; Pai MR; Khadilkar UN
Indian J Pathol Microbiol; 2009; 52(3):332-8. PubMed ID: 19679954
[TBL] [Abstract][Full Text] [Related]
10. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications.
Shin YK; Choi YL; Choi EY; Kim MK; Kook MC; Chung J; Choi YK; Kim HS; Song HG; Park SH
Cancer Immunol Immunother; 2003 Aug; 52(8):506-12. PubMed ID: 12768327
[TBL] [Abstract][Full Text] [Related]
11. JL1, a novel differentiation antigen of human cortical thymocyte.
Park SH; Bae YM; Kwon HJ; Kim TJ; Kim J; Lee SJ; Lee SK
J Exp Med; 1993 Oct; 178(4):1447-51. PubMed ID: 8376947
[TBL] [Abstract][Full Text] [Related]
12. Diminished expression of CD19 in B-cell lymphomas.
Yang W; Agrawal N; Patel J; Edinger A; Osei E; Thut D; Powers J; Meyerson H
Cytometry B Clin Cytom; 2005 Jan; 63(1):28-35. PubMed ID: 15624204
[TBL] [Abstract][Full Text] [Related]
13. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL).
Perea G; Altés A; Bellido M; Aventín A; Bordes R; Ayats R; Remacha AF; Espinosa I; Briones J; Sierra J; Nomdedéu JF
Histopathology; 2004 Sep; 45(3):268-74. PubMed ID: 15330805
[TBL] [Abstract][Full Text] [Related]
15. Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement in B-cell lymphoma.
Gomyo H; Shimoyama M; Minagawa K; Yakushijin K; Urahama N; Okamura A; Yamamoto K; Ito M; Chihara K; Hayashi Y; Matsui T
Haematologica; 2003 Dec; 88(12):1358-65. PubMed ID: 14687988
[TBL] [Abstract][Full Text] [Related]
16. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas.
Chan WK; Au WY; Wong CY; Liang R; Leung AY; Kwong YL; Khong PL
Clin Nucl Med; 2010 Aug; 35(8):571-5. PubMed ID: 20631501
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow involvement in non-Hodgkin's lymphoma: increased diagnostic sensitivity by combination of immunocytology, cytomorphology and trephine histology.
Schwonzen M; Pohl C; Steinmetz T; Wickramanayake PD; Thiele J; Diehl V
Br J Haematol; 1992 Jul; 81(3):362-9. PubMed ID: 1382545
[TBL] [Abstract][Full Text] [Related]
18. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas.
Palacio C; Acebedo G; Navarrete M; Ruiz-Marcellán C; Sanchez C; Blanco A; López A
Haematologica; 2001 Sep; 86(9):934-40. PubMed ID: 11532621
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow flow cytometry in staging of patients with B-cell non-Hodgkin lymphoma.
Kim B; Lee ST; Kim HJ; Kim SH
Ann Lab Med; 2015 Mar; 35(2):187-93. PubMed ID: 25729719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
